The role of indoleamine 2,3-dioxygenase in virus-induced asthma exacerbations - IDO and virus-induced asthma exacerbations

Academisch Medisch Centrum0 个研究点目标入组 42 人开始时间: 待定最近更新: 2024年5月13日

适应症

试验速览

暂无简介。

•Inclusion criteria for allergic asthma patients:
•- Controlled, intermittant to mild persistant asthma patients (according to the updated (2007) GINA guidelines);
•- FEV1 at baseline at least 80% of the predicted value;
•- baseline bronchial hyperresponsiveness to histamine (PC20histamine) between 0.25 and 8 mg/ml;
•- Skin-prick test positive to common allergens;
•- Patients are treated with inhaled beta-2-agonists on demand only (twice a week or less);
•- Age between 18 and 40 years;;Inclusion citeria for healthy subjects:
•- FEV1 at baseline at least 80% of the predicted value and baseline;
•- PC20histamine above 16 mg/ml;
•- Skin-prick test negative to common allergens;
•- Age between 18 and 40 years;

•Exclusion criteria for allergic asthma patients:
•- Moderate to severe asthma patients (according to the updated (2007) GINA guidelines);
•- Allergic asthma patients with daily symptoms;
•- Nocturnal symptoms more than once a week;
•- Patients who have had an exacerbation during the past 6 months, as indicated by a course of systemic steroids or antibiotics;
•- Patients that used (inhaled) steroids less than 6 weeks prior to the study;
•- Smokers;
•- Ex-smokers ( < 12 months or > 5 packyears);
•- Circulating antibodies against rhinovirus type 16;
•- Patients who are in close contact with young children (< 2 years), either professional or family related.;Exclusion criteria for healthy subjects:
•- Healthy subjects with a history of pulmonary complaints;
•- Smokers;
•- Ex-smokers ( < 12 months or > 5 packyears);
•- Circulating antibodies against rhinovirus type 16;
•- Patients who are in close contact with young children (< 2 years), either professional or family related.

发起方